Overview

"This work represents the first comprehensive publication in the innovative field of pharmacogenomics, a field which is set to revolutionize pharmaceutical research. In addition to renowned editors, the list of contributors is a ""who-is-who"" in the field. Broad coverage of all aspects of pharmacogenomics with a full presentation of applications to disease conditions is featured. Anyone involved in pharmaceutical research and drug development needs this book to keep up with this new and revolutionary approach"

Full Product Details

Author:   Julio Licinio ,  Ma-Li Wong
Publisher:   Wiley-VCH Verlag GmbH
Imprint:   Wiley-VCH Verlag GmbH
Dimensions:   Width: 18.60cm , Height: 2.90cm , Length: 24.20cm
Weight:   1.176kg
ISBN:  

9783527303809

ISBN 10:   3527303804
Pages:   599
Publication Date:   09 April 2002
Audience:   College/higher education ,  Professional and scholarly ,  Undergraduate ,  Postgraduate, Research & Scholarly
Format:   Hardback
Publisher's Status:   Out of Print
Availability:   Awaiting stock  

Table of Contents

Preface.List of Contributors.Color Plates.Introduction to Pharmacogenomics: Promises, Opportunities, and Limitations (U. Meyer). The Human Genome (S. Broder, et al.). Turning SNPs into Useful Makers of Drug Response (J. McCarthy). Association Studies in Pharmacogenomics (L. Essioux, et al.). Genomics Application that Facilitate the Understanding of Drug Action and Toxicity (L. Furness). The Role of Pharmacogenetics in Drug Discovery and Therapeutics (K. Lindpaintner). Pharmacogenomics and Drug Design (P. Dean, et al.). The Pharmacogenomics of Human P--Glycoprotein (M. Fromm & M. Eichelbaum). Pharmacogenomics of Drug Transporters (R. Tirona & R. Kim). Pharmacogenomics of Asthma Treatment (L. Palmer, et al.). Endothelial Cells are Targets for Hydroxy Urea: Relevance to the Current Therapeutic Strategy in Sickle Cell Disease (C. Lapoumeroulie, et al.). Pharmacogenomics and Complex Cardiovascular Disease -- Clinical Studies in Candidate Genes (B. Winkelmann, et al.). Pharmacogenomics of Lipid--Lowering Agents (M. Hoffmann, et al.). Pharmacogenomics of Chemotherapeutic Agents in Cancer Treatment (F. Innocenti, et al.). Pharmacogenomics of the Blood--Brain Barrier (J.--M. Scherrmann). Pharmacogenomics and the Treatment of Neurological Disease (D. Goldstein, et al.). Pharmacogenomics of Neurodegenerative Diseases: Examples and Perspectives (P. Hantraye, et al.). Psychiatric Pharmacogenetics: Prediction of Treatment Outcomes in Schizophrenia (M. Masellis, et al.). Pharmacogenomics of Major Depression and Antidepressant Treatment (M.--L. Wong, et al.). Pharmacogenomics of Bipolar Disorder (H. Manji, et al.). Pharmacogenomics of Alcoholism (T. Hurley, et al.). Pharmacogenomics of Tobacco Addiction (E. Johnstone, et al.). Pharmacogenomics of Opioid Systems (T. Reisine). Ethnicity and Pharmacogenomics (H. McLeod & M. Ameyaw). Pharmacogenomics: Ensuring Equity Regarding Drugs Based on Genetic Difference (P. Epps & M. Rothstein). Translation of Vascular Proteomics into Individualized Therapeutics (R. Pasqualini & W. Arap). Glossary of Key Terms in Molecular Genetics of Pharmacogenomics (B. Winkelmann, et al.). Index.

Reviews

...a well--organized presentation of the current level of development in pharmacogenomics and is one of the most promising milestones in understanding pharmacogenomics. (Pharmaceutical Research, Vol. 19, No. 10, October 2002)

Author Information

Tab Content 6

Author Website:  

Countries Available

All regions